Ivona Filic

Ivona Filic

Auto-generated profile, based on publicly available information

Ivona Filic

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
CMChevaun D. Morrison-Smith
Chevaun D. Morrison-Smith
TKTatiana M. Knox
Tatiana M. Knox
IFIvona Filic
Ivona Filic
KSKara M. Soroko
Kara M. Soroko
BEBenjamin K. Eschle
Benjamin K. Eschle
CFChristopher Alexander French
Christopher Alexander French
NUT midline carcinoma (NMC) is a rare, aggressive subtype of squamous carcinoma that is driven by the BRD4-NUT fusion oncoprotein. BRD4, a BET protein, binds to chromatin through its two bromodomains, and NUT recruits the p300 histone acetyltransferse (HAT) to activate transcription of oncogenic target genes. BET-selective bromodomain inhibitors have demonstrated on-target activity in patients with NMC, but with limited efficacy. P300, like BRD4, contains a bromodomain. We show that combining selective p300/CBP and BET bromodomain inhibitors, GNE-781 and OTX015, respectively, induces cooperative depletion of MYC and synergistic inhibition of NMC growth. Treatment of NMC cells with the novel dual p300/CBP and BET bromodomain–selective inhibitor, NEO2734, potently inhibits growth and induces differentiation of NMC cells in vitro; findings that correspond with potentiated transcriptional effects from combined BET and p300 bromodomain inhibition. In three disseminated NMC xenograft models, NEO2734 provided greater growth inhibition, with tumor regression and significant survival benefit seen in two of three models, compared with a lead clinical BET inhibitor or “standard” chemotherapy. Our findings provide a strong rationale for clinical study of NEO2734 in patients with NMC. Moreover, the synergistic inhibition of NMC growth by CBP/p300 and BET bromodomain inhibition lays the groundwork for greater mechanistic understanding of the interplay between p300 and BRD4-NUT that drives this cancer.

20 July 2021 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
HSHitoshi Shiota
Hitoshi Shiota
AAArtyom A. Alekseyenko
Artyom A. Alekseyenko
ZWZhipeng A. Wang
Zhipeng A. Wang
IFIvona Filic
Ivona Filic
TKTatiana M. Knox
Tatiana M. Knox
CFChristopher Alexander French
Christopher Alexander French
NUT carcinoma (NC), characterized most commonly by the BRD4-NUTM1 fusion, is a rare, aggressive variant of squamous carcinoma with no effective treatment. BRD4-NUT drives growth and maintains the poorly differentiated state of NC by activating pro-growth genes such as MYC, through the formation of massive, hyperacetylated, superenhancer-like domains termed megadomains. BRD4-NUT–mediated hyperacetylation of chromatin is facilitated by the chromatin-targeting tandem bromodomains of BRD4, combined with NUT, which recruits the histone acetyltransferase, p300. Here, we developed a high-throughput small-molecule screen to identify inhibitors of transcriptional activation by NUT. In this dCAS9-based GFP-reporter assay, the strongest hits were diverse histone deacetylase (HDAC) inhibitors. Two structurally unrelated HDAC inhibitors, panobinostat and the novel compound, IRBM6, both repressed growth and induced differentiation of NC cells in proportion to their inhibition of NUT transcriptional activity. These two compounds repressed transcription of megadomain-associated oncogenic genes, such as MYC and SOX2, while upregulating pro-differentiation, non-megadomain–associated genes, including JUN, FOS, and key cell-cycle regulators, such as CDKN1A. The transcriptional changes correlate with depletion of BRD4-NUT from megadomains, and redistribution of the p300/CBP-associated chromatin acetylation mark, H3K27ac, away from megadomains toward regular enhancer regions previously populated by H3K27ac. In NC xenograft models, we demonstrated that suppression of tumor growth by panobinostat was comparable with that of bromodomain inhibition, and when combined they improved both survival and growth suppression. Implications: The findings provide mechanistic and preclinical rationale for the use of HDAC inhibitors, alone or combined with other agents, in the treatment of NUT carcinoma.

3 April 2023
Verified
Other
Open access
HSHitoshi Shiota
Hitoshi Shiota
AAArtyom A. Alekseyenko
Artyom A. Alekseyenko
ZWZhipeng A. Wang
Zhipeng A. Wang
IFIvona Filic
Ivona Filic
TKTatiana M. Knox
Tatiana M. Knox
CFChristopher Alexander French
Christopher Alexander French
Supplementary Figure Legends 1-4

3 April 2023
Verified
Other
Open access
HSHitoshi Shiota
Hitoshi Shiota
AAArtyom A. Alekseyenko
Artyom A. Alekseyenko
ZWZhipeng A. Wang
Zhipeng A. Wang
IFIvona Filic
Ivona Filic
TKTatiana M. Knox
Tatiana M. Knox
CFChristopher Alexander French
Christopher Alexander French
NUT carcinoma (NC), characterized most commonly by the BRD4-NUTM1 fusion, is a rare, aggressive variant of squamous carcinoma with no effective treatment. BRD4-NUT drives growth and maintains the poorly differentiated state of NC by activating pro-growth genes such as MYC, through the formation of massive, hyperacetylated, superenhancer-like domains termed megadomains. BRD4-NUT–mediated hyperacetylation of chromatin is facilitated by the chromatin-targeting tandem bromodomains of BRD4, combined with NUT, which recruits the histone acetyltransferase, p300. Here, we developed a high-throughput small-molecule screen to identify inhibitors of transcriptional activation by NUT. In this dCAS9-based GFP-reporter assay, the strongest hits were diverse histone deacetylase (HDAC) inhibitors. Two structurally unrelated HDAC inhibitors, panobinostat and the novel compound, IRBM6, both repressed growth and induced differentiation of NC cells in proportion to their inhibition of NUT transcriptional activity. These two compounds repressed transcription of megadomain-associated oncogenic genes, such as MYC and SOX2, while upregulating pro-differentiation, non-megadomain–associated genes, including JUN, FOS, and key cell-cycle regulators, such as CDKN1A. The transcriptional changes correlate with depletion of BRD4-NUT from megadomains, and redistribution of the p300/CBP-associated chromatin acetylation mark, H3K27ac, away from megadomains toward regular enhancer regions previously populated by H3K27ac. In NC xenograft models, we demonstrated that suppression of tumor growth by panobinostat was comparable with that of bromodomain inhibition, and when combined they improved both survival and growth suppression.Implications:The findings provide mechanistic and preclinical rationale for the use of HDAC inhibitors, alone or combined with other agents, in the treatment of NUT carcinoma.

3 April 2023
Verified
Other
Open access
HSHitoshi Shiota
Hitoshi Shiota
AAArtyom A. Alekseyenko
Artyom A. Alekseyenko
ZWZhipeng A. Wang
Zhipeng A. Wang
IFIvona Filic
Ivona Filic
TKTatiana M. Knox
Tatiana M. Knox
CFChristopher Alexander French
Christopher Alexander French

3 April 2023
Verified
Other
Open access
CMChevaun D. Morrison-Smith
Chevaun D. Morrison-Smith
TKTatiana M. Knox
Tatiana M. Knox
IFIvona Filic
Ivona Filic
KSKara M. Soroko
Kara M. Soroko
BEBenjamin K. Eschle
Benjamin K. Eschle
CFChristopher Alexander French
Christopher Alexander French